TYENNE Q Code: Q5135
Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
Q4 2026 Medicare Payment Limit for Q5135, effective October 1, 2026: $4.37 per HCPCS billing unit, up 7.7% from $4.056. From CMS's final file.
Drug & Product Overview
About TYENNE
Tyenne is a medication aligned to the HCPCS Q Code: Q5135 for billing, pricing, and reimbursement purposes in the United States. This Immunology medication is administered via the intravenous or subcutaneous routes and manufactured by multiple companies.
According to CMS Drug Use Information: This medication is used to treat rheumatoid arthritis in adults and in children (such as polyarticular juvenile idiopathic arthritis-PJIA, systemic juvenile idiopathic arthritis-SJIA). It helps to reduce pain and swelling due to rheumatoid arthritis. Tocilizumab is used to treat giant cell arteritis. It helps to reduce swelling in your blood vessels so blood can flow more easily. This medication is also used to slow down the decrease in lung function in people with a certain type of lung disease (systemic sclerosis-associated interstitial lung disease - SSc-ILD). Tocilizumab belongs to a class of drugs known as Interleukin-6 (IL-6) blockers. It works by blocking IL-6, a substance made by the body that causes swelling (inflammation). This monograph is about the following tocilizumab products: tocilizumab, tocilizumab-aazg, and tocilizumab-anoh.
Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.
NDC Code Information
Based on publicly available CMS files. Showing 5 of 7 NDCs — log in for the full crosswalk.
| NDC Code | Drug | Manufacturer | Billing Units / Pkg | Package Size |
|---|---|---|---|---|
| 65219-0584-01 | Tyenne | Fresenius Kabi USA, LLC | 162 | 162 MG / 0.9 ML |
| 65219-0586-04 | Tyenne | Fresenius Kabi USA, LLC | 162 | 162 MG / 0.9 ML |
| 65219-0590-04 | Tyenne | Fresenius Kabi USA, LLC | 80 | 80 MG / 4 ML |
| 65219-0592-10 | Tyenne | Fresenius Kabi USA, LLC | 200 | 200 MG / 10 ML |
| 65219-0594-20 | Tyenne | Fresenius Kabi USA, LLC | 400 | 400 MG / 20 ML |
| •••••-••••-•• Log in to view | TYENNE | •••••••••••• Log in to view | •••• Log in to view | ••• •• / • •• Log in to view |
| •••••-••••-•• Log in to view | TYENNE | •••••••••••• Log in to view | •••• Log in to view | ••• •• / • •• Log in to view |
TYENNE Pricing & Reimbursement
National median reimbursement across major commercial payers.
Create an account on PayerPrice for more information →
Historical Graphing and Billing Calculator
Log in to calculate billing and reimbursement with live ASP, WAC & AWP pricing.
Login to use the calculator →Tocilizumab Biosimilar Information:
TYENNE Approval Date: March 5, 2024
| Product Name | HCPCS Code | Active Ingredient | BLA Type |
|---|---|---|---|
| Actemra | J3262 | Tocilizumab | 351(a) Originator Product |
| Tofidence | Q0234 | Tocilizumab | 351(k) Biosimilar |
| Tofidence | Q5133 | Tocilizumab | 351(k) Biosimilar |
| Tyenne | Q0238 | Tocilizumab | 351(k) Biosimilar |
| Tyenne | Q5135 | Tocilizumab | 351(k) Biosimilar |
| Avtozma | Q0237 | Tocilizumab | 351(k) Interchangeable |
| Avtozma | Q5156 | Tocilizumab | 351(k) Interchangeable |
TYENNE CPT Administration Codes
The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.
| CPT Code | Description |
|---|---|
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) |
| 96372 Login for More | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular Login for More |
This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →
TYENNE Medically Unlikely Edits (MUE)
The most billing units of Q5135 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.
MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →
TYENNE Clinical Information
Indications and drug classification.
This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.
Login for BuyandBill.com Analytics
Unlock deeper insights with BuyandBill’s Comparative Report!
- Compare ASP, WAC, and AWP across drugs.
- Visualize Drug Price Movement Over Time
- Tailor reports to drug class, manufacturer, or HCPCS Code.
- Compare Biosimilar and 505(b)(2) products.
Frequently Asked Questions
Is there an available TYENNE billing and coding guide?
Are there any available TYENNE patient assistance programs?
Where can I find TYENNE prescribing information?
Where can I find TYENNE side effect information?
Does billing TYENNE require JZ/JW wastage modifiers?
About BuyandBill.com:
The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.
Related Drug Codes
Explore billing, coding, and pricing for drugs related to TYENNE.
